Latest news

We sat down with Stephen, our Research Scientist, to learn more about the journey that led him to join the PlaqueTec team, and to highlight his role in the ongoing BIOPATTERN trial. Before joining PlaqueTec in 2024, Stephen completed a PhD at the Babraham Institute in Cambridge, where his researched focused on neutrophil-dependent immunity. After finishing his PhD, Stephen worked in a postdoctoral position at the Institute, where he collaborated with PlaqueTec to validate a d

Published in Drug Discovery World, Deputy Editor Diana Turner asked key players from across the life sciences industry what key trends and innovations in drug discovery to look out for in 2026.

Published in Today’s Clinical Lab, Dr Simon Williams, General Manager at PlaqueTec, highlights a need to better characterise, risk stratify, and treat individual patients with coronary artery disease (CAD) to reduce the significant residual risk that remains from current, largely population-based approaches.

A recent review by Prof Peter Libby and Prof Oliver Soehnlein “Inflammation in atherosclerosis: Lessons and therapeutic implications,” published in the journal Immunity, highlights that inflammation drives all stages of atherosclerosis, from lesion initiation to plaque rupture, through diverse immune cell populations.

Published in European Biopharmaceutical Review , Dr Simon Williams, General Manager at PlaqueTec, explores the global impact of coronary...

Pre-specified interim analysis reveals differences in protein concentration between systemic blood and blood from diseased coronary...

Project evaluated small molecules against novel target in coronary artery disease discovered by PlaqueTec Bespoke cell-based assay...

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), has...

Campus Innovation Award (CIA)-funded project evaluated lead compounds predicted to bind a pro-inflammatory protein discovered by...

The financing was led by Lord Moynihan of Chelsea alongside The Future Fund, with support from existing investors Funding will support...

Collaboration to develop a bespoke cell phenotyping assay for human blood Project aims to investigate cell types present in coronary...

Published in Cardiovascular News, Dr Stephen Hoole, Chief Investigator of our BIOPATTERN trial and Consultant Cardiologist at Royal...

PlaqueTec receives the UK’s MHRA approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.

What is the relationship between protein concentration at site of coronary atheroma and fibrous cap thickness?